Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02796898 · ClinicalTrials.gov registry record · Phase 1
Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer
A Phase 1 study of Prostate Cancer and Rising Prostate Specific Antigen (PSA), sponsored by Tyme.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 5
- Study locations
NCT02796898: Completed Phase 1 study of Prostate Cancer and Rising Prostate Specific Antigen (PSA), sponsored by Tyme.
NCT02796898 is a Phase 1 study of Prostate Cancer and Rising Prostate Specific Antigen (PSA) that has completed, run by Tyme. The registered enrollment target is 23 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02796898, a Phase 1 study of Prostate Cancer and Rising Prostate Specific Antigen (PSA), has completed, sponsored by Tyme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, pharmacokinetics, and efficacy of SM88 in patients with prostate cancer
Primary Outcome
During 4 days of single dose PK evaluations \[Phase 1b only\], and six 4-week treatment cycles, we will determine if patients in consecutive cohorts experience any dose limiting toxicity to determine MTD, or a complete response with no DLTs observed to determine the optimum dose.
Conditions Studied
Interventions
- DRUG SM88 (Cohort 1)
- DRUG SM88 (Cohort 2)
Study Locations (5)
New York
- AccuMed Research Associates - Garden City
- Montefiore Medical Center- Montefiore Medical Park - The Bronx
- Eastchester Center for Cancer Care - The Bronx
New Jersey
- AdvanceMed Research - Lawrence
Pennsylvania
- MidLantic Urology - Bala-Cynwyd
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2016-06 |
| Est. Completion | 2019-05-30 |
| Phase | Phase 1 |
What the finished NCT02796898 record still lists
NCT02796898 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which SM88 (Cohort 1) is the first listed.
NCT02796898 lists 5 locations in 3 states (New York, New Jersey, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT02796898 about?
NCT02796898 is a clinical study titled "Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer". The purpose of this study is to evaluate the safety, pharmacokinetics, and efficacy of SM88 in patients with prostate cancer
What is the current status of trial NCT02796898?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2016-06. Estimated completion is 2019-05-30.
What conditions does trial NCT02796898 study?
This clinical trial studies the following conditions: Prostate Cancer, Rising Prostate Specific Antigen (PSA).
What interventions are being tested in trial NCT02796898?
The interventions under investigation include: SM88 (Cohort 1) (DRUG), SM88 (Cohort 2) (DRUG).
Who is sponsoring clinical trial NCT02796898?
This trial is sponsored by Tyme, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02796898 being conducted?
This trial has 5 study locations across New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02796898's enrollment target sits among peer trials
23 640th of 735 higher than 92 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia